CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

Completed · Phase 2

Conditions studied: Leukemia

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission.

Key facts

Study ID

NCT00003673

Run by

Pfizer

People needed

55

Starts

1998-03-01

Expected to finish

1999-03-01

Last updated by the study team

2012-08-22

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States
• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• New England Medical Center Hospital — Boston, Massachusetts, United States
• Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
• Long Island Jewish Medical Center — New Hyde Park, New York, United States
• New York Presbyterian Hospital - Cornell Campus — New York, New York, United States
• State University of New York Health Sciences Center - Stony Brook — Stony Brook, New York, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.